

North Yorkshire & York Area Prescribing Committee

Wednesday 3rd May 2023
2pm – 4.30pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Voting Member	Dec 2022	Feb 2023	Mar 2023	Apr 2023	May 2023
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Y	Rachel Ainger	Y	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Y	Y	Y	Y	Y
Laura Angus	Head of Medicines Optimisation and Interim Chief Pharmacist at Humber, & North Yorkshire ICS	City of York Place	Y	Y	Y	Y (from Item 15)	Fasial Majothi	Y
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	City of York Place	Y	Y	Y	Y	Apols	Apols
Dr William Ovenden	GP	City of York Place	Y	Y	Y	Y	Y	Apols
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Y	Apols	Y	Y
Dr Ben Walker (till Feb 2023)	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Y	Apols	Victoria Millson	Victoria Millson	Apols
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Jane Crewe	Y
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Apols	Y (from item 10)	Apols	X
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Y	Apols	Y	Y	Y
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Y (till item 9)	Apols	Y	Apols	Y
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Kurt Ramsden	Apols	Kurt Ramsden	Kurt Ramsden	Kurt Ramsden
Anita Dobson	Public Health representative	City of York Council	Y	Apols	Y	Apols	Resigned	
Alison Levin	Finance representative	North Yorkshire Place	Y	Jo Horsfall	Jo Horsfall	Jo Horsfall	Apols	Jo Horsfall
Hazel Mitford	lay/patient representative		Y	Y	Y	Apols	Apols	Y
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Y	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire Place	N	Y	Y	Y	Y	Y
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Y	Y	See above	Y
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	Y	See above	Y
Sara Abbas-Llewelyn / Emily Parkes	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	N	X	X	X	Sara Abbas-Llewelyn	Sara Abbas-Llewelyn
Ian Dean	LPC Representative		N	Y	Y	Y	Y	Apols
Dr Sally Tyrer	LMC Representative		N	X	X	X	X	Jane Raja
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	X	For item 17	Y	Y	Apols

The meeting was quorate with 10 out of 14 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

Part 1

1. Apologies for absence and quoracy check

Shaun O'Connell, Ian Dean, William Ovenden, Sara Moore, Victoria Millson.

Note: Victoria Millson will be leaving HDFT so a new consultant representative from HDFT will be sought.

2. Declarations of interest

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today's meeting:

Nil declared.

3. Minutes of previous APC & decision summary of meeting held on 5th April 2023

The minutes of the April 2023 APC were approved as a true and accurate record subject to the following amendments:

- Item 10 – clarify somatrogen is AMBER SI in paediatrics and not shared care in adults. Only licensed for use in adults.
- Item 12 – Buvidal[®] – add as an action: KR to confirm management of acute withdrawal in patients on Buvidal[®] admitted to secondary care and confirm process for updating patient records in a timely manner to show they are on Buvidal[®].

4. Outcome of items referred to April 2023 IPMOC

Dexcom ONE and CGM – awaiting further discussions at ICB as to cost implications for proposed updates to CGM policy in line with NICE guidance from March 2022 given the current financial position of the ICB.

Items previously referred to IPMOC still awaiting confirmation of scheme of delegation for decision-making by IPMOC.

5. Matters arising not on the agenda & declarations of AOB

AOB – Nil matters arising.

Dexcom ONE

There has been a significant shift in the ICB financial situation that may result in a delay in implementing the new NICE diabetes guidance position. Consequently, the commissioning of Dexcom ONE will also be delayed as we are currently unable to make any new financial investments. It is unclear how long this situation will continue for.

However, an interim position has proposed a solution that could potentially allow HNY to commission Dexcom ONE for all patients who were previously eligible for Freestyle Libre (FSL) under the current HNY FSL commissioning position. Since these patients are already eligible for

FSL, they would also be eligible for Dexcom ONE, and there would be no financial impact in doing so since both devices cost the same. This may also allow patients access to an alternative device prior to other specialist CGM devices provided via the hospital.

The APC agreed to support this proposal and to ask ICB to update current Flash/CG policy to commission Dexcom ONE for all patients who were previously eligible on the FSL commissioning position.

ACTION:

- **KL to check same proposal has been discussed at Humber APC.**
- **KL to take interim proposal to ICB to update current Flash/CG policy to commission Dexcom ONE for all patients who were previously eligible on the current HN YFSL commissioning positions, given that this should be cost neutral.**

6. Action log

Guidelines for recognition and management of non- IgE cow's milk allergy in children – partial update

CR has sought clarifications to p6: Step 2-2 Re-challenge with cow's milk using iMAP guidelines after 4-week period (can be omitted when symptoms are severe) before guideline is returned to APC for approval.

Confirmed with authors that this exclusion is more for exceptional cases and allows for some clinical judgement.

CR to check WO is happy with this response and agree some additional wording to be added to the guideline with the author.

Formulary Updates approved at April 2023 APC

JC/SAL have updates Y&S and Harrogate formularies. ITEM NOW CLOSED.

Outstanding actions from previous APC meetings

North Yorkshire and York APC – updated Terms of Reference and Scheme of Delegation

To come back to June 2023 APC.

Current vacancies in membership and non-attendance

To come back to today's APC with paper on changes to operation of APC meetings.

Bicalutamide RAG status

Action still in progress.

Diazoxide for chronic intractable hypoglycaemia

KW/SM/JC still to develop shared care guideline to be presented to future APC for approval.

Medical Devices Commissioning and Formulary Position

RDTG to review previous MCC commissioning positions on individual medical devices in Q1 2023/24.

Vulval treatment advice proforma - HDFT

On today's agenda.

Oral minoxidil for androgenic alopecia

ICB policy alignment group have confirmed they will review this particular policy across the ICB when the NICE TA for baricitinib is published. Agreed no further action for item for APC until this policy is reviewed by the ICB.

Vitamin D guidance - reviewed and updated

FM/SM have now added in additional information from York guidance and this is in the process of being published on websites. ITEM NOW CLOSED.

Valproate medicines for patients of child-bearing potential

LA will circulate final approved version of SCG. ITEM NOW CLOSED.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

Part 2 – Governance

7. Update on meeting of APC membership to help improve operation of the APC

A paper was presented to the APC as an output of the review of how the APC currently operates, with the aims of:

- Enhancing engagement of the whole APC membership and attending partners
- Ask members to help shape APC processes for a smoother running APC
- Improve efficiency and address any frustrations associated with APC processes
- Create an all-round more satisfying, professional and comfortable APC meeting where all attendees feel (and are made to feel) comfortable to attend and speak

The recommendations within the paper were approved by the APC.

A calendar of dates for deadlines for submission of agenda items is being created and will be circulated.

The APC Terms of Reference will be updated to reflect these changes and will come to the next APC for approval.

ACTION:

- **LK/LA/RDTC to update APC Terms of Reference to reflect these changes and bring to the next APC for approval.**

Part 3 – Mental Health

8. TEVV Drug & Therapeutics Committee feedback - May 23

Circulated for information.

Part 4 – Formulary issues

9. Appeals against previous APC decisions

None received.

10. Formulary NICE TAs and MHRA Drug Safety Update – March 2023

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
- TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
- TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
- HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia

All the above TAs are NHSE-commissioned and would therefore have no cost impact to the ICB.

The drugs in the following TAs which are ICB-commissioned to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 – noted that at present both oral Nirmatrelvir plus

ritonavir (Paxlovid) and IV Sotrovimab remain free of charge to the ICB until national stocks are exhausted, estimated to be 2025 for Nirmatrelvir plus ritonavir and for a further 6-12 months for IV Sotrovimab, after which there will be a financial cost to the ICB. The potential cost impact in the future falls above the delegated authority of the APC so this TA will be referred to the IPMOC.

Decision on the following ICB-commissioned drugs in the following TAs to be deferred:

- TA875: Semaglutide for managing overweight and obesity – decision deferred until product is launched in UK and price is known so accurate local cost impact can be calculated.
- TA877: Finerenone for treating chronic kidney disease in type 2 diabetes - decision deferred till next month to get accurate local patient numbers and consult with renal team.

Medicines Safety MHRA Drug Safety Update – March 2023

The group noted the drug safety updates for March 2023. The links are to be added to the relevant sections of the formulary.

Agreed that pholcodine should be deleted from the Harrogate formulary now that its license has been withdrawn by the MHRA.

ACTION:

- **JC/SAL to update the formulary websites.**
- **JC to speak to renal team re TA877: Finerenone for treating chronic kidney disease in type 2 diabetes.**

11. Other formulary issues

Nil this month.

12. New Drug Applications

Estradiol 10 microgram vaginal tablets (Vagirux®)

The APC discussed the formulary application received for Estradiol 10 microgram vaginal tablets (Vagirux®) for the treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women on the basis that has less plastic waste than current brands.

This is currently the cheapest brand available. The current brand on the formulary is Vagifem®. Other brands are already listed on the formulary.

The application was approved as a GREEN drug with Estradiol 10 microgram vaginal tablets to be listed generically on the formulary.

The application was approved as a GREEN drug. To be prescribed by brand. This is currently the cheapest and most environmentally sustainable brand available.

ACTION:

- **JC/SAL to update the formulary websites.**

13. Compassionate use/free of charge scheme requests

Nil this month.

14. RMOC update

Nil this month.

Part 5 – Shared Care and Guidelines (non-mental health)

15. Shared care guidelines for approval

Octreotide for late dumping syndrome and hypoglycaemia

A shared care guideline for octreotide for late dumping syndrome and hypoglycaemia was presented to the APC.

These are off-label indications approved for addition to the Harrogate formulary by Harrogate

APC in January 2021.

APC discussed and agreed that octreotide should remain a RED drug for these indications and therefore this shared care guideline was not required. This was because patient numbers are very low for these indications and primary care expressed a number of concerns around the risks in them prescribing/dispensing for these indications.

Part 6 – Other items of business

16. RDTC Publication -Transfer of prescribing from private provider to NHS GP

Circulated for information. This document is intended to provide some advice/points for consideration for primary care when considering such requests. RDTC documents such as this are not intended as policy and cannot be as such because of the process followed in their development. Noted RDTC have received some comments since publication in March 2023 and will be considering minor amendments with an updated version expected in June 2023.

When an updated version is available it will go to IPMOC to consider adoption across Humber and North Yorkshire.

17. Vulval Clinic treatment advice proforma V2

This was re-presented to the APC following consultation with YSFT as requested by the APC.

Developed originally by HDFT team to allow specialist nurses on the Women's Unit to recommend treatments for vulval conditions for patients seen in their nurse-led clinic. This was in conjunction with the pharmacy department who agreed this would be instead of PGDs for the various treatments. This would allow specialist nurses to recommend treatments to GPs when there was no doctor present in the Women's Unit. YSFT now confirmed happy with content.

After discussion, the APC agreed to explore with HDFT if this treatment advice note is really needed as should be using hospital outpatient pharmacy in first instance. YSFT confirmed they have no real desire or need to adopt this proforma.

ACTION:

- **KW to explore with HDFT if this treatment advice note is really needed as should be using hospital outpatient pharmacy in first instance.**

18. Faricimab (NICE TA 799 and 800) and Ranibizumab biosimilar update

An update on uptake of faricimab and biosimilar ranibizumab was given to the APC. Faricimab was approved locally in line with the NICE Tas, with aflibercept remaining the first-choice treatment option because of cost. Faricimab has the advantage of being able to be given less frequently but costs more than aflibercept. There are currently significant capacity issues within ophthalmology to be able to see new patients and administer these injections for existing patients.

The APC agreed that the ICB should explore current capacity issues in ophthalmology alongside a possible change to current local guidance so faricimab can be used in line with NICE TA for use in wAMD and DMO but on the proviso that biosimilar ranibizumab uptake rates are improved. It noted that this needs full consideration by the ICB of the cost impact on any changes.

ACTION:

- **KL to raise with HNY Eye Care Group and link with the ICB Executive Director of Clinical and Professional.**

Part 7 – Standing items (for information only)

19. IPMOC minutes – March 2023

Circulated for information.

20. TEWV D&T minutes – January 2023

Circulated for information.

21. **York & Scarborough Trust Drug and Therapeutics Committee minutes – since November 2022**
Not yet available.
22. **Harrogate Trust Medicines and Therapeutics Group minutes – since September 2022**
Not yet available.
23. **County Durham & Tees Valley APC minutes – March 2023**
Not yet available.
24. **Yorkshire ICS APC minutes – since November 2022**
Not yet available.
25. **Humber APC minutes – April 2023**
Circulated for information.
26. **Humber APC decisions & recommendations – April 2023**
Circulated for information.
27. **RDTC Monthly Horizon scanning – April 2023**
Circulated for information.
28. **NENC Medicines Committee decision Summary – April 2023**
Not yet available.

Any Other Business

Nil

Formulary applications received for June 2023 meeting

The APC have received the following formulary applications to date for the June 2023 APC meeting:

- Nil to date.

Date and time of next meeting

Wednesday 7th June 2023, 2pm – 4.30pm, virtual meeting via Microsoft Teams